Type 2 diabetes mellitus in 2010: Individualizing treatment targets in diabetes care

Nature Reviews Endocrinology

Volumn 7, Issue 2, 2011, Pages 67-68

  Buse, John B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; SIMVASTATIN;

ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LASER COAGULATION; LIPID BLOOD LEVEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VITRECTOMY;

BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79251613671     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.230     Document Type: Article

References (8)

1. Skyler, J. S. et al. intensive glycemic control and the prevention of cardiovascular events: implications of the aCCOrD, aDvanCe, and va diabetes trials: a position statement of the american Diabetes association and a scientific statement of the american College of Cardiology Foundation and the american Heart association. Diabetes Care 32, 187-192 (2009).
2. riddle, M. C. et al. epidemiologic relationships between a1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the aCCOrD trial. Diabetes Care 33, 983-990 (2010).
3. aCCOrD Study Group. effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
4. aCCOrD Study Group. effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
5. The aCCOrD Study Group and aCCOrD eye Study Group. effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 363, 233-244 (2010).
6. ismail-Beigi, F. et al. effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the aCCOrD randomised trial. Lancet 376, 419-430 (2010).
7. Kahn, r. et al. age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375, 1365-1374 (2010).
8. Buse, J. B. et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. a randomized, controlled trial. Ann. Intern. Med. 2010 Dec 6 [epub ahead of print].